본문으로 건너뛰기
← 뒤로

Management of Functional Esophagogastric Junction Outflow Obstruction: A Systematic Review.

Journal of clinical gastroenterology 2020 Vol.54(1) p. 35-42

Garbarino S, von Isenburg M, Fisher DA, Leiman DA

관련 도메인

📝 환자 설명용 한 줄

[GOALS] Awareness of functional esophagogastric junction outflow obstruction (fEGJOO) has increased, but because there is no consensus on its management, we performed a systematic review of the litera

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 184
  • 추적기간 15 months
  • 연구 설계 systematic review

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Garbarino S, von Isenburg M, et al. (2020). Management of Functional Esophagogastric Junction Outflow Obstruction: A Systematic Review.. Journal of clinical gastroenterology, 54(1), 35-42. https://doi.org/10.1097/MCG.0000000000001156
MLA Garbarino S, et al.. "Management of Functional Esophagogastric Junction Outflow Obstruction: A Systematic Review.." Journal of clinical gastroenterology, vol. 54, no. 1, 2020, pp. 35-42.
PMID 30575636

Abstract

[GOALS] Awareness of functional esophagogastric junction outflow obstruction (fEGJOO) has increased, but because there is no consensus on its management, we performed a systematic review of the literature to explore treatment strategies and outcomes.

[BACKGROUND] EGJOO is a heterogenous disorder defined by high-resolution manometry parameters of elevated integrated relaxation pressure with preserved esophageal peristalsis. The etiology may be mechanical obstruction or idiopathic, the latter being fEGJOO.

[STUDY] The PubMed/MEDLINE, Embase, and the Cochrane library electronic databases were searched through June 2018 for all studies of adult patients describing a treatment strategy for fEGJOO or incomplete lower esophageal sphincter relaxation. The search strategy yielded 1792 studies and 8 (0.4%) met inclusion criteria.

[RESULTS] All but one included studies were retrospective (n=184 patients). There were 5 interventions described, with botulinum toxin (Botox) injection (n=69) and expectant management (n=82) the most frequently reported, with success rates of 58% and 54%, respectively. There was substantial heterogeneity among patients and treatments were not directly compared, though reported symptom resolution was similar among all strategies with a mean follow-up time of 15 months.

[CONCLUSIONS] There are a variety of management strategies available for fEGJOO and some patients may not require any intervention. However, among 4 potential approaches aimed at disrupting lower esophageal sphincter hypertonicity, the largest existing evidence base supports either a therapeutic challenge of Botox injection or watchful waiting. Ultimately, these data indicate the need for further study with controlled trials to identify a definitive approach.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botox 보툴리눔독소 주사 dict 2
시술 botulinum toxin 보툴리눔독소 주사 dict 1

MeSH Terms

Adult; Botulinum Toxins, Type A; Disease Management; Esophageal Motility Disorders; Esophagogastric Junction; Female; Humans; Injections, Intramuscular; Male; Prospective Studies; Retrospective Studies; Treatment Outcome; Watchful Waiting

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문